{"entity":{"id":"nct04875585","kind":"trial","name":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC","aka":["INNWOP1"],"tldr":"A phase 2 trial of pembrolizumab and lenvatinib in lung cancer, run by Medical University Innsbruck, now recruiting.","summary":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC is a phase 2, interventional study registered as NCT04875585 by Medical University Innsbruck, with a registry enrolment figure of 33 participants, started 2021-05-12 and due to reach its primary completion in 2023-12. Interventions recorded: neoadjuvant therapy with Pembrolizumab/Lenvatinib; Surgery; Adjuvant Treatment Phase. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Major pathological response after neoadjuvant immunotherapy in combination with angiogenesis inhibition. Lung eligibility wording from the registry: \"Histologically confirmed primary diagnosis of resectable NSCLC, stages IA3-IIIA (max\". Sites: Austria. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04875585","url":"https://clinicaltrials.gov/study/NCT04875585"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["pembrolizumab","lenvatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04875585","phase":"2","setting":"Phase II Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib and Adjuvant Pembrolizumab in Patients With Surgically Resectable Non-Small- Cell Lung Cancer (NSCLC)","sponsor":"Medical University Innsbruck","enrolled":33,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04875585/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}